Arsenic trioxide

Generic Name: Arsenic trioxide

Brand Names: Trisenox, Arsenic trioxide Accord, Arsenic trioxide Mylan, Arsenic trioxide medac

Drug Type: Small Molecule

Chemical Formula: As_₂O_₃

CAS Number: 1327-53-3

Unique Ingredient Identifier: S7V92P67HO

Background: Arsenic trioxide is a chemotherapeutic agent of idiopathic function used to treat leukemia that is unresponsive to first line agents. It is suspected that arsenic trisulfide induces cancer cells to undergo apoptosis. In general, arsenic is known to be a naturally toxic substance capable of eliciting a variety of dangerous adverse effects. The enzyme thioredoxin reductase has recently been identified as a target for arsenic trioxide.

Indication: For induction of remission and consolidation in patients with acute promyelocytic leukemia (APL), and whose APL is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression

Associated Conditions: Acute Promyelocytic Leukemia, Refractory Acute Promyelocytic Leukemia, Relapsed Acute Promyelocytic Leukemia

Clinical Trials

Transcatheter Arterial Chemoembolization (TACE) in Combination With Arsenic Trioxide Versus TACE in the Treatment of Middle-advanced Primary Hepatocellular Carcinoma (HCC) Patients

Phase 2

Conditions: Primary Hepatocellular Carcinoma

Interventions: Drug: TACE
Drug: Arsenic trioxide

First Posted Date: 2016-11-06

Last Posted Date: 2017-02-23

Lead Sponsor: Hunan Provincial People's Hospital

Target Recruit Count: 190

Registration Number: NCT02956772

Locations: 🇨🇳
The First Affiliated Hospital of University of South China, Hengyang, Hunan, China
🇨🇳
Guizhou Cancer Hospital, Guiyang, Guizhou, China
🇨🇳
Guizhou Province Tumor Hospital, Guiyang, Guizhou, China

and more 6 locations

Treatment of Non-high-risk Acute Promyelocytic Leukemia (APL) With Realgar-Indigo Naturalis Formula (RIF)

Phase 3

Conditions: Acute Promyelocytic Leukemia

Interventions: Drug: Realgar-Indigo naturalis formula
Drug: all-trans retinoic acid
Drug: Arsenic trioxide
Drug: Hydroxyurea

First Posted Date: 2016-09-14

Last Posted Date: 2021-09-08

Lead Sponsor: First Affiliated Hospital Xi'an Jiaotong University

Target Recruit Count: 110

Registration Number: NCT02899169

Locations: 🇨🇳
First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China

Arsenic Trioxide and Itraconazole in Treating Patients With Advanced Basal Cell Cancer

Early Phase 1

Withdrawn

Conditions: Skin Basal Cell Carcinoma

Interventions: Drug: Arsenic Trioxide
Drug: Itraconazole
Other: Laboratory Biomarker Analysis

First Posted Date: 2016-03-04

Last Posted Date: 2020-10-22

Lead Sponsor: Jean Yuh Tang

Registration Number: NCT02699723

Study for Patients With Newly Diagnosed, High-risk Acute Promyelocytic Leukemia

Phase 3

Completed

Conditions: Acute Promyelocytic Leukemia

Interventions: Drug: Arsenic trioxide
Drug: Idarubicin
Drug: Cytarabine
Drug: Tretinoin
Drug: Mitoxantrone
Drug: Mercaptopurine
Drug: Methotrexate

First Posted Date: 2016-02-23

Last Posted Date: 2025-02-26

Lead Sponsor: Technische Universität Dresden

Target Recruit Count: 135

Registration Number: NCT02688140

Locations: 🇩🇪
OSHO study group, Multiple Locations, Germany
🇩🇪
SAL study group, Multiple Locations, Germany
🇳🇱
HOVON study group, Multiple Locations, Netherlands

and more 5 locations

Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic Leukemia

Phase 3

Active, not recruiting

Conditions: Acute Promyelocytic Leukemia With t(15;17)(q24.1;q21.2); PML-RARA

Interventions: Drug: Arsenic Trioxide
Drug: Cytarabine
Drug: Dexamethasone
Drug: Idarubicin
Other: Laboratory Biomarker Analysis
Drug: Mitoxantrone Hydrochloride
Other: Quality-of-Life Assessment
Other: Questionnaire Administration
Drug: Tretinoin

First Posted Date: 2015-01-15

Last Posted Date: 2024-11-07

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 158

Registration Number: NCT02339740

Locations: 🇺🇸
University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
🇺🇸
Rady Children's Hospital - San Diego, San Diego, California, United States
🇺🇸
Naval Medical Center -San Diego, San Diego, California, United States

and more 171 locations

Leukemia SPORE Phase II DAC Study for R/R and Elderly Acute AML and MDS

Phase 2

Completed

Conditions: Acute Myeloid Leukemia
Chronic Myelomonocytic Leukemia
Myelodysplastic Syndrome

Interventions: Drug: Decitabine
Drug: Carboplatin
Drug: Arsenic trioxide

First Posted Date: 2014-07-15

Last Posted Date: 2021-05-19

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 92

Registration Number: NCT02190695

Locations: 🇺🇸
Temple BMT Program at Jeanes Hospital, Philadelphia, Pennsylvania, United States
🇺🇸
M.D. Anderson Cancer Center, Houston, Texas, United States

Icotinib and Arsenic Trioxide in Treating Non-small-cell Lung Cancer Patients With Resistance to EGFR-TKI

Phase 1

Conditions: Non-small Cell Lung Cancer

Interventions: Drug: Icotinib
Drug: Arsenic trioxide

First Posted Date: 2014-02-20

Last Posted Date: 2015-03-13

Lead Sponsor: Betta Pharmaceuticals Co., Ltd.

Target Recruit Count: 9

Registration Number: NCT02066870

Locations: 🇨🇳
Department of Medical Oncology, Cancer Institute/Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China

Arsenic Trioxide TACE and Intravenous Administration in Unresectable Hepatocellular Carcinoma

Phase 2

Conditions: Carcinoma, Hepatocellular

Interventions: Device: Arsenic trioxide TACE
Drug: Arsenic trioxide intravenous infusion
Drug: lipiodol
Drug: NaCl solution

First Posted Date: 2013-05-24

Last Posted Date: 2013-06-05

Lead Sponsor: Guangdong Provincial People's Hospital

Target Recruit Count: 258

Registration Number: NCT01861912

Arsenic Trioxide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Phase 2

Withdrawn

Conditions: Adult Acute Monoblastic Leukemia (M5a)
Adult Acute Myeloblastic Leukemia With Maturation (M2)
Adult Acute Megakaryoblastic Leukemia (M7)
Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
Adult Acute Myelomonocytic Leukemia (M4)
Adult Erythroleukemia (M6a)
Adult Pure Erythroid Leukemia (M6b)
Recurrent Adult Acute Myeloid Leukemia
Adult Acute Monocytic Leukemia (M5b)
Adult Acute Myeloblastic Leukemia Without Maturation (M1)